Last update 08 May 2025

Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.

Private Company|2022|Shanghai Shi, China

Overview

Tags

Respiratory Diseases
Otorhinolaryngologic Diseases
Congenital Disorders
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Immune System Diseases1
Endocrinology and Metabolic Disease1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Monoclonal antibody1
Top 5 TargetCount
TSLP(Thymic stromal lymphopoietin)1
KRAS G12C(GTPase KRas G12C)1

Related

2
Drugs associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
Garsorasib
Target
KRAS G12C
Mechanism
KRAS G12C inhibitors
Active Org.
InventisBio, Co., Ltd.InventisBio, Co., Ltd. [+2]
Originator Org.
InventisBio, Co., Ltd.InventisBio, Co., Ltd.
Active Indication
KRAS G12C mutant Non-small Cell Lung Cancer [+7]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date05 Nov 2024
Bosakitug
Target
TSLP
Mechanism
TSLP inhibitors
Active Org.
Shanghai Zhengda Tianqing Pharmaceutical Co., Ltd. [+5]
Originator Org.
Biosion, Inc.Biosion, Inc.
Active Indication
Asthma [+7]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
CTR20244467
/ RecruitingPhase 2
评价 TQC2731 注射液在中度至极重度慢性阻塞性肺疾病患者的有效性、安全性和药代动力学的多中心、随机、双盲、安慰剂对照 Ⅱ 期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of TQC2731 injection in patients with moderate to very severe chronic obstructive pulmonary disease
100 Clinical Results associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
Login to view more data
100 Deals associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Garsorasib
 ( KRAS G12C )		KRAS G12C mutant Non-small Cell Lung Cancer
More
Approved
Bosakitug
 ( TSLP )		Pulmonary Disease, Chronic Obstructive
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free